Replies to post #409338 on Anavex Life Sciences Corp (AVXL)

[Doc328]

I have no doubt that Covid-19 affected the OLE but the company falsely communicated along the way. Covid did not make Missling lie.

On clinicaltrials.gov, the 9/29/2020 initial OLE listing was n= 100 [Anticipated] and on 10/5/2020 it was listed as n= 120 [Anticipated]. Then despite the real n being known, the 1/15/2022 update states n=132 [Actual]. This was reaffirmed 7/29/2022 as n=132 [Actual]. Yes they changed the number HIGHER even after knowing the exact value.

Was he afraid to admit the study had too low an n to be meaningful - it's not like we weren't going to eventually know. Or is he just that bad with details - not a good quality for a CEO wanting to get FDA approval.

clinicaltrials.gov link

a link to the Covid-19 measures of Leon Research, Anavex's CRO in Spain